This article was originally published here<\/p>\n
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020 Jul 22:e1654. doi: 10.1002\/wnan.1654. Online ahead of print.<\/p>\n
ABSTRACT<\/p>\n
Lung cancer is considered to cause the most cancer-related deaths worldwide. Due to the deficiency in early-stage diagnostics and local invasion or distant metastasis, the first line of treatment for most patients unsuitable for surgery is chemotherapy, targeted therapy or immunotherapy. Nanocarriers with the function of improving drug solubility, in vivo stability, drug distribution in the body, and sustained and targeted delivery, can effectively improve the effect of drug treatment and reduce toxic and side effects, and have been used in clinical treatment for lung cancer and many types of cancers. Here, we review nanoparticle (NP) formulation for lung cancer treatment including liposomes, polymers, and inorganic NPs via systemic and inhaled administration, and highlight the works of overcoming drug resistance and improving cancer immunotherapy. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.<\/p>\n
PMID:32700465 | DOI:10.1002\/wnan.1654<\/p>\n
<\/p>\n
Read this article:<\/p>\n
Nanomedicine in lung cancer: Current states of overcoming drug resistance and improving cancer immunotherapy - DocWire News<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" This article was originally published here Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020 Jul 22:e1654. doi: 10.1002\/wnan.1654. Continue reading